PDF(Pubmed)
Abstract：
Despite advances in the genomic classification of breast cancer, current clinical tests and treatment decisions are commonly based on protein-level information. Nowadays breast cancer clinical treatment selection is based on the immunohistochemical (IHC) determination of four protein biomarkers: Estrogen Receptor 1 (ESR1), Progesterone Receptor (PGR), Human Epidermal Growth Factor Receptor 2 (HER2), and proliferation marker Ki-67. The prognostic correlation of tumor-infiltrating T cells has been widely studied in breast cancer, but tumor-infiltrating B cells have not received so much attention. We aimed to find a correlation between immunohistochemical results and a proteomic approach in measuring the expression of proteins isolated from B-cell lymphocytes in peripheral blood samples. Shotgun proteomic analysis was chosen for its key advantage over other proteomic methods, which is its comprehensive and untargeted approach to analyzing proteins. This approach facilitates better characterization of disease-associated changes at the protein level. We identified 18 proteins in B cell lymphocytes with a significant fold change of more than 2, which have promising potential to serve as breast cancer biomarkers in the future.
摘要：
尽管乳腺癌的基因组分类取得了进展，当前的临床试验和治疗决策通常基于蛋白质水平的信息。如今，乳腺癌的临床治疗选择是基于四种蛋白质生物标志物的免疫组织化学（IHC）测定：雌激素受体1（ESR1），孕酮受体(PGR),人表皮生长因子受体2(HER2),和增殖标记Ki-67。肿瘤浸润T细胞的预后相关性在乳腺癌中已被广泛研究。但是肿瘤浸润B细胞并没有受到如此多的关注。我们旨在发现免疫组织化学结果与蛋白质组学方法之间的相关性，以测量从外周血样本中B细胞淋巴细胞分离的蛋白质的表达。shot弹枪蛋白质组学分析是由于其优于其他蛋白质组学方法的关键优势，这是它的全面和无针对性的方法来分析蛋白质。这种方法有助于在蛋白质水平更好地表征疾病相关的变化。我们在B细胞淋巴细胞中鉴定出18种蛋白质，其显著倍数变化超过2倍，具有未来作为乳腺癌生物标志物的潜力。
